Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.62 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.62 |
| ▸ | GSK3A | P49840 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | PRKX | P51817 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454347 | 0.93 | HDAC6 (0.70) | HDAC6HDAC2HDAC8HPGDEPHX2 | |
| SCHEMBL12604611 | 0.91 | EPHX2 (0.78) | HDAC6HDAC2HDAC8EPHX2CA2 | |
| SCHEMBL18868425 | 0.91 | EPHX2 (0.78) | HDAC6HDAC2HDAC8EPHX2CA2 | |
| SCHEMBL11900090 | 0.91 | HDAC6 (0.85) | HDAC6HDAC2HDAC8HPGDEPHX2 | |
| SCHEMBL4981515 | 0.90 | EPHX2 (0.77) | HDAC6HDAC2HDAC8EPHX2CA2 | |
| Hydrochloric Acid SCHEMBL30918901 | 0.89 | EPHX2 (0.76) | HDAC6HDAC2HDAC8EPHX2CA2 | |
| Succinic Acid SCHEMBL11587387 | 0.87 | HDAC1 (0.62) | HDAC6HDAC2HDAC8HPGDEPHX2 | |
| SCHEMBL457082 | 0.87 | HDAC6 (0.79) | HDAC6HDAC2HDAC8HPGDEPHX2 | |
| SCHEMBL6140514 | 0.86 | HDAC6 (0.72) | HDAC6HDAC2HDAC8HPGDEPHX2 | |
| SCHEMBL6843720 | 0.85 | HDAC6 (0.77) | HDAC6HDAC2HDAC8HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| EP-0078845-B1 | ANTI-CONVULSANT | CLARK, Charles Randall (US) | 1987-02-04 | — | — | EP | claimed |
| EP-0078845-A4 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-09-02 | — | — | EP | claimed |
| EP-0078845-A1 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-05-18 | — | — | EP | claimed |
| US-4379165-A | Anti-convulsant | RESEARCH CORPORATION (US) | 1983-04-05 | — | — | US | claimed |
| WO-1982004046-A1 | ANTI-CONVULSANT | CLARK CHARLES RANDALL | 1982-11-25 | — | — | WO | claimed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| CN-104478780-B | Acylpyrrole small-molecular organic compound, derivatives of organic compound as well as application and preparation method of acylpyrrole small-molecular organic compound and derivatives of organic compound | 华东师范大学 | 2017-04-19 | — | — | CN | disclosed |
| EP-2488032-B1 | PROSTAGLANDIN TRANSPORTER INHIBITORS AND USES THEREOF | EINSTEIN COLL MED (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-0078845-A4 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-09-02 | — | — | EP | disclosed |
| EP-0078845-A1 | ANTI-CONVULSANT. | CLARK CHARLES RANDALL | 1983-05-18 | — | — | EP | disclosed |
| US-4379165-A | Anti-convulsant | RESEARCH CORPORATION (US) | 1983-04-05 | — | — | US | disclosed |
| WO-1982004046-A1 | ANTI-CONVULSANT | CLARK CHARLES RANDALL | 1982-11-25 | — | — | WO | disclosed |
| US-4118503-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4117138-A | ANTIULCER | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4064264-A | Pyrrolidonecarboxylic acid derivatives as anti-ulcer agents | PFIZER INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HDAC6 1604/4885HDAC2 1409/4885HDAC8 3493/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HDAC6 1677/4885HDAC2 1530/4885HDAC8 3648/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HDAC6 1677/4885HDAC2 1530/4885HDAC8 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.